[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Periodontal Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

May 2024 | 128 pages | ID: PC4B43B9B98EEN
IMARC Group

US$ 6,499.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The 7 major periodontal disease markets reached a value of US$ 218.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 329.1 Million by 2034, exhibiting a growth rate (CAGR) of 3.8% during 2024-2034.

The periodontal disease market has been comprehensively analyzed in IMARC's new report titled "Periodontal Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Periodontal disease refers to a chronic inflammatory condition that affects the gums and supporting structures of the teeth. This illness usually begins with the formation of plaque, a sticky film of bacteria that forms on the teeth. The symptoms of the ailment can vary depending on the stage and severity of the disease, but individuals suffering from the disorder mainly experience swollen, red, and tender gums. Numerous other indications associated with the condition include persistent bad breath, toothache, sensitive teeth, receding gums, painful chewing, bleeding, pocket formation that can trap bacteria and food debris, etc. The diagnosis of periodontal disease involves a combination of clinical examination, medical history assessments, and several other laboratory tests. A healthcare provider will initially examine the gums, teeth, and mouth to check for any signs of bleeding, inflammation, or recession of the gums, which are indicative of the ailment. In some cases, an additional workup may be required to determine the cause of underlying symptoms. This may include imaging procedures, like X-rays, to assess bone levels or dental issues among patients.

The increasing prevalence of dental plaque that can harden into tartar, leading to irritation and inflammation in the gums, is primarily driving the periodontal disease market. Moreover, the rising incidences of various associated risk factors, such as smoking, genetic predisposition, bad oral hygiene, hormonal changes, a weakened immune system, certain systemic diseases, etc., are also bolstering the market growth. In addition to this, the widespread adoption of topical antimicrobial gels containing antibiotics or antiseptics, which can be applied directly to the infected gum pockets to control bacteria and promote healing, is acting as another significant growth-inducing factor. Furthermore, the inflating demand for soft tissue grafts, in which healthy tissue is placed in areas of gum recession to help in covering exposed tooth roots, is also creating a positive outlook for the market. Additionally, the emerging popularity of dental lasers for treating the ailment, since they work by stimulating cellular activity and accelerating the regeneration of gum tissue, leading to quicker recovery times in patients, is expected to drive the periodontal disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the periodontal disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for periodontal disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the periodontal disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the periodontal disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the periodontal disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current periodontal disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the periodontal disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the periodontal disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the periodontal disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of periodontal disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of periodontal disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of periodontal disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with periodontal disease across the seven major markets?
What is the size of the periodontal disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of periodontal disease?
What will be the growth rate of patients across the seven major markets?

Periodontal Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for periodontal disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the periodontal disease market?
What are the key regulatory events related to the periodontal disease market?
What is the structure of clinical trial landscape by status related to the periodontal disease market?
What is the structure of clinical trial landscape by phase related to the periodontal disease market?
What is the structure of clinical trial landscape by route of administration related to the periodontal disease market?
1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PERIODONTAL DISEASE - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 PERIODONTAL DISEASE - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 PERIODONTAL DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
  7.2.1 Epidemiology Scenario (2018-2023)
  7.2.2 Epidemiology Forecast (2024-2034)
  7.2.3 Epidemiology by Age (2018-2034)
  7.2.4 Epidemiology by Gender (2018-2034)
  7.2.5 Diagnosed Cases (2018-2034)
  7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
  7.3.1 Epidemiology Scenario (2018-2023)
  7.3.2 Epidemiology Forecast (2024-2034)
  7.3.3 Epidemiology by Age (2018-2034)
  7.3.4 Epidemiology by Gender (2018-2034)
  7.3.5 Diagnosed Cases (2018-2034)
  7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
  7.4.1 Epidemiology Scenario (2018-2023)
  7.4.2 Epidemiology Forecast (2024-2034)
  7.4.3 Epidemiology by Age (2018-2034)
  7.4.4 Epidemiology by Gender (2018-2034)
  7.4.5 Diagnosed Cases (2018-2034)
  7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
  7.5.1 Epidemiology Scenario (2018-2023)
  7.5.2 Epidemiology Forecast (2024-2034)
  7.5.3 Epidemiology by Age (2018-2034)
  7.5.4 Epidemiology by Gender (2018-2034)
  7.5.5 Diagnosed Cases (2018-2034)
  7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
  7.6.1 Epidemiology Scenario (2018-2023)
  7.6.2 Epidemiology Forecast (2024-2034)
  7.6.3 Epidemiology by Age (2018-2034)
  7.6.4 Epidemiology by Gender (2018-2034)
  7.6.5 Diagnosed Cases (2018-2034)
  7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
  7.7.1 Epidemiology Scenario (2018-2023)
  7.7.2 Epidemiology Forecast (2024-2034)
  7.7.3 Epidemiology by Age (2018-2034)
  7.7.4 Epidemiology by Gender (2018-2034)
  7.7.5 Diagnosed Cases (2018-2034)
  7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
  7.8.1 Epidemiology Scenario (2018-2023)
  7.8.2 Epidemiology Forecast (2024-2034)
  7.8.3 Epidemiology by Age (2018-2034)
  7.8.4 Epidemiology by Gender (2018-2034)
  7.8.5 Diagnosed Cases (2018-2034)
  7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
  7.9.1 Epidemiology Scenario (2018-2023)
  7.9.2 Epidemiology Forecast (2024-2034)
  7.9.3 Epidemiology by Age (2018-2034)
  7.9.4 Epidemiology by Gender (2018-2034)
  7.9.5 Diagnosed Cases (2018-2034)
  7.9.6 Patient Pool/Treated Cases (2018-2034)

8 PERIODONTAL DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 PERIODONTAL DISEASE - UNMET NEEDS

10 PERIODONTAL DISEASE - KEY ENDPOINTS OF TREATMENT

11 PERIODONTAL DISEASE - MARKETED PRODUCTS

11.1 List of Periodontal Disease Marketed Drugs Across the Top 7 Markets
  11.1.1 Arestin (Minocycline controlled-release) - OraPharma
    11.1.1.1 Drug Overview
    11.1.1.2 Mechanism of Action
    11.1.1.3 Regulatory Status
    11.1.1.4 Clinical Trial Results
    11.1.1.5 Sales Across Major Markets
  11.1.2 Atridox (Doxycycline hyclate) - QLT USA
    11.1.2.1 Drug Overview
    11.1.2.2 Mechanism of Action
    11.1.2.3 Regulatory Status
    11.1.2.4 Clinical Trial Results
    11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 PERIODONTAL DISEASE - PIPELINE DRUGS

12.1 List of Periodontal Disease Pipeline Drugs Across the Top 7 Markets
  12.1.1 Drug Name – Company Name
    12.1.1.1 Drug Overview
    12.1.1.2 Mechanism of Action
    12.1.1.3 Clinical Trial Results
    12.1.1.4 Safety and Efficacy
    12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.

13. PERIODONTAL DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PERIODONTAL DISEASE – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 PERIODONTAL DISEASE - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
  15.2.1 Periodontal Disease - Market Size
    15.2.1.1 Market Size (2018-2023)
    15.2.1.2 Market Forecast (2024-2034)
  15.2.2 Periodontal Disease - Market Size by Therapies
    15.2.2.1 Market Size by Therapies (2018-2023)
    15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
  15.3.1 Periodontal Disease - Market Size
    15.3.1.1 Market Size (2018-2023)
    15.3.1.2 Market Forecast (2024-2034)
  15.3.2 Periodontal Disease - Market Size by Therapies
    15.3.2.1 Market Size by Therapies (2018-2023)
    15.3.2.2 Market Forecast by Therapies (2024-2034)
  15.3.3 Periodontal Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
  15.4.1 Periodontal Disease - Market Size
    15.4.1.1 Market Size (2018-2023)
    15.4.1.2 Market Forecast (2024-2034)
  15.4.2 Periodontal Disease - Market Size by Therapies
    15.4.2.1 Market Size by Therapies (2018-2023)
    15.4.2.2 Market Forecast by Therapies (2024-2034)
  15.4.3 Periodontal Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
  15.5.1 Periodontal Disease - Market Size
    15.5.1.1 Market Size (2018-2023)
    15.5.1.2 Market Forecast (2024-2034)
  15.5.2 Periodontal Disease - Market Size by Therapies
    15.5.2.1 Market Size by Therapies (2018-2023)
    15.5.2.2 Market Forecast by Therapies (2024-2034)
  15.5.3 Periodontal Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
  15.6.1 Periodontal Disease - Market Size
    15.6.1.1 Market Size (2018-2023)
    15.6.1.2 Market Forecast (2024-2034)
  15.6.2 Periodontal Disease - Market Size by Therapies
    15.6.2.1 Market Size by Therapies (2018-2023)
    15.6.2.2 Market Forecast by Therapies (2024-2034)
  15.6.3 Periodontal Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
  15.7.1 Periodontal Disease - Market Size
    15.7.1.1 Market Size (2018-2023)
    15.7.1.2 Market Forecast (2024-2034)
  15.7.2 Periodontal Disease - Market Size by Therapies
    15.7.2.1 Market Size by Therapies (2018-2023)
    15.7.2.2 Market Forecast by Therapies (2024-2034)
  15.7.3 Periodontal Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
  15.8.1 Periodontal Disease - Market Size
    15.8.1.1 Market Size (2018-2023)
    15.8.1.2 Market Forecast (2024-2034)
  15.8.2 Periodontal Disease - Market Size by Therapies
    15.8.2.1 Market Size by Therapies (2018-2023)
    15.8.2.2 Market Forecast by Therapies (2024-2034)
  15.8.3 Periodontal Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
  15.9.1 Periodontal Disease - Market Size
    15.9.1.1 Market Size (2018-2023)
    15.9.1.2 Market Forecast (2024-2034)
  15.9.2 Periodontal Disease - Market Size by Therapies
    15.9.2.1 Market Size by Therapies (2018-2023)
    15.9.2.2 Market Forecast by Therapies (2024-2034)
  15.9.3 Periodontal Disease - Access and Reimbursement Overview

16 PERIODONTAL DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PERIODONTAL DISEASE MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 PERIODONTAL DISEASE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX


More Publications